Connect with us

Health

NAFDAC Raises Alarm Over Fake Augmentin In Circulation

Published

on

fake augmentin

 

Advertisement

The National Agency for Food and Drugs Administration and Control has raised alarm over the circulation of a suspected fake Augmentin 625mg Tabs in the country.

Augumentin is an antibiotic medication used for the treatment of different types of bacterial infections.

Advertisement

In a statement on Monday, the agency said the falsified antibiotic has batch number 562626, a manufacturing date of April 2021 and expiry date of April 2024.

It added that the medication has a NAFDAC registration number of 04-1928 but failed to meet labeling requirements.

Advertisement

The alert signed by the management of NAFDAC and titled ‘NAFDAC Alert And Sensitization Of The Public On Suspected Falsified Augmentin 625mg’ was obtained by our correspondent on the agency’s website.

NAFDAC said the suspected falsified Augmentin which was manufactured in April 2021 would expire on April 2024.

Advertisement

“The logo “gsk” is not properly positioned as on the original. The listed information indicates the product is falsified and counterfeited.

“In view of the above, NAFDAC has notified all its formations in the zones and 36 states of the federation including the FCT to carry out surveillance and mop up the falsified Augmentin tablets.”

Advertisement

It added, “Please note that the genuine Augmentin 625mg has legible product labeling information including date markings – expiration and manufactured dates, batch number and NAFDAC registration number.

“NAFDAC advise to wholesalers, distributors, and pharmacies that medicines should be obtained from authorized/licensed suppliers, increased vigilance is hereby encouraged within the supply chain to avoid infiltration of the falsified product. The products’ authenticity, physical condition and labels should be carefully checked.

Advertisement

“NAFDAC implores healthcare providers to ensure vigilance to prevent the administration of falsified products to unsuspecting patients. Members of the public in possession of the above suspected counterfeit product are advised to discontinue sale or use and submit stock to the nearest NAFDAC office.

“Healthcare providers and the public should notify the nearest NAFDAC office of any information concerning the distribution, sale, and use of the falsified version of the Augmentin product.

Advertisement

Report any suspicion of adverse drug reaction and substandard and falsified medicines to NAFDAC on 0800-162-3322 or email: [email protected]

Advertisement

Advertisement
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

three × 5 =

Advertisement

Trending

X